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Rett syndrome (RTT) is an early-onset neurodevelopmental disorder that almost exclusively affects girls 
and is totally disabling. Three genes have been identified that cause RTT: MECP2, CDKL5 and FOXG1. 
However, the etiology of some of RTT patients still remains unknown. Recently, next generation 
sequencing (NGS) has promoted genetic diagnoses because of the quickness and affordability of the 
method. To evaluate the usefulness of NGS in genetic diagnosis, we present the genetic study of RTT-
like patients using different techniques based on this technology. We studied 1577 patients with RTT-
like clinical diagnoses and reviewed patients who were previously studied and thought to have RTT 
genes by Sanger sequencing. Genetically, 477 of 1577 patients with a RTT-like suspicion have been 
diagnosed. Positive results were found in 30% by Sanger sequencing, 23% with a custom panel, 24% 
with a commercial panel and 32% with whole exome sequencing. A genetic study using NGS allows the 
study of a larger number of genes associated with RTT-like symptoms simultaneously, providing genetic 
study of a wider group of patients as well as significantly reducing the response time and cost of the 
study.
Rett syndrome (RTT; MIM# 312750) is a neurodevelopmental disorder of early onset that affects girls almost 
exclusively. RTT was originally described in the 1960s by Andreas Rett1. This syndrome is first recognized in 
infancy with a period of apparently normal development (up to the age of 6–18 months), followed by a regression 
characterized by loss of speech and purposeful hand use and motor apraxia that may be associated with epi-
lepsy and dysautonomic features, including disturbed breathing, sleep and gastrointestinal motility1,2. RTT has 
an incidence of 1:10,000 live female births and is the second cause of intellectual disability after Down’s syndrome 
in females3. RTT was clinically cataloged into classic and atypical forms of the disease. However, these criteria 
have undergone several updates over the past three decades. Consensus criteria have been established that distin-
guish RTT patients into the individual classifications of classic or typical RTT and the atypical or variant forms 
of RTT4–6.
A large number of reports support the evidence that mutations in the Methyl CpG binding protein 2 gene 
(MECP2; MIM *300005) are the major causes of classical RTT7,8. Over 95% of the cases are explained by more 
than 800 reported mutations in the methyl CpG-binding protein 2 gene (MECP2) (RettBASE: MECP2 Variation 
Database)9,10. MeCP2 is a transcriptional regulatory protein, and in its absence, a large number of genes exhibit 
abnormal expression with implications in the balance between synaptic excitation and inhibition11.
Although the majority of RTT patients have mutations in the MECP2 gene10, approximately 5% of classical 
RTT and 25% of variant RTT patients are negative for MECP2 mutation6,12. In this variant RTT group of patients, 
some have mutations in other genes that are also associated with RTT: cyclin-dependent kinase-like5 (CDKL5; 
MIM *300203), which is described in individuals with an early seizure onset variant of RTT13, and Forkhead box 
protein G1 (FOXG1; MIM *164874), which is responsible for the congenital variant of RTT14. In addition, with 
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the introduction of next generation sequencing (NGS), other genes without previous relation to RTT have been 
associated with RTT-like phenotypes, such as myocyte-specific enhancer factor 2C (MEF2C; MIM *600662) and 
transcription factor 4 (TCF4; *602272)15. However, the etiology of a subset of patients with a clinical diagnosis of 
RTT or RTT-like symptoms remains unknown.
In recent years, NGS has emerged as a potentially powerful tool for the study of this type of genetic disease16,17. 
Now, multiple genes can be sequenced at the same time and at a comparable cost to the Sanger analysis of only 
one single gene18,19. However, for genetic diagnostics, Sanger sequencing still remains necessary to validate the 
detected variants to avoid false positives.
Here, we present the retrospective results from our group using Sanger sequencing and three different 
approaches for library construction of NGS libraries. Our main goal was to assess the relative advantages and 
disadvantages of each methodology for diagnostic purposes.
Results
A total of 1577 patients with RTT-like syndrome were genetically analyzed between 1999 and 2016 at Sant Joan 
de Déu Hospital, Barcelona (see Fig. S1). These patients had been diagnosed following the usual clinical param-
eters6 and according to the recently revised RTT Search International Consortium criteria and nomenclature6. 
Throughout the Sanger period, 84% of RTT classical phenotypes and 16% of atypical phenotypes were recruited 
for study. From 2012, a wider group of patients was recruited, not only RTT classical and atypical but also with 
RTT-like features, due to the incorporation of the NGS technologies.
Four approaches were used to genetically analyze all RTT patients who were recruited. A total of 1341 patients 
were studied based on Sanger sequencing (SS). The high throughput approaches were based on three distinct 
gene library preparations. First, 242 patients were studied using the Haloplex Custom Panel (HCP, Agilent 
Technologies) (Santa Clara, California), including 46 that came from a negative study of SS. Second, 51 patients 
were studied using the TruSight One panel (TSO, Illumina) (San Diego, California), including 11 who came from 
a negative study of HCP. Finally, 22 patients declared as negative-SS and 3 declared as negative-HCP were studied 
using the SeqCap EZ Human Exome v2.0 and v3.0 (WES, Roche NimbleGen) (Madison, Wisconsin). SS was used 
to study the exons and surroundings of the three genes associated with RTT (MECP2, CDKL5 and FOXG1). HCP 
is a custom panel of 17 genes designed to cover the exons and surroundings of genes associated with RTT-like 
phenotypes. TSO targets 4,813 genes associated with a clinical phenotype, including RTT-like phenotypes. The 
WES kit was used to target all human coding exons, including genes covered by panels.
Run and Mapping Quality. A summary of quality control data is represented in Fig. 1a. The total number 
of passing filter reads (PF reads) was approximately 9 times higher in TSO (approx. 28 million reads) than HCP 
(approx. 3 million reads), whereas WES (approx. 80 million reads) was 3 times higher than TSO. The percentage 
of unique–mapping reads aligned to the reference sequence was higher in TSO (99.5%) and WES (99.4% and 
99.2%) than HCP (97.8%). In addition, the unique–mapping reads aligned with a mapping quality Q20 or higher, 
indicating that the aligner estimates a 1/100 (or smaller) chance of a wrong alignment, was also higher in TSO 
(94.8%) and WES (93.0 and 85.7%) than HCP (90.6%).
Figure 1. Comparison of main coverage metrics. Average of all samples analyzed for the four different 
approaches. (a) Bar plots with 95% confidence interval for the four approaches. Alignment metrics: passing 
filter (PF) reads; percentage of PF reads that aligned to the reference sequence; and percentage of PF reads that 
were aligned to the reference sequence with a mapping quality of Q20 or higher signifying. (b) Tukey boxplots: 
Mean read depth; percentage of bases covered at C1; and percentage of bases covered at C30.
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Target Regions, Read Depth and Coverage. The diagnosis regions of interest for a given set of genes 
that are related to RTT-like features is defined as the sum of the targets defined by the coding bases of the exons 
plus a 25 bp flanking region. Three sets of genes of interest were defined where each set included the previous 
one: RTT list, which included the 3 genes related to RTT; RTT-like list, 3+60 genes related to RTT-like disease; 
and RTT+EEP list, 3+14 RTT-like genes and 526 genes related to RTT-like features and epileptic encephalopa-
thy (EEP) (Table 1S). Depending on the NGS methods and analyses performed, we evaluated the set of 17 genes 
common to both panels (TSO and HCP) and the WES, or the set of 605 genes most included in the TSO and all 
of them in the WES. The gene lists are shown in Supplementary Table 1S.
The performance of the three approaches was compared as if they were four since the WES samples were 
captured with two different kits, i.e., with SureSelect version 2.0 in 2011 (SCv2) and version 3.0 (SCv3) in 2014. 
In this study, 30 reads per base was considered the minimum coverage (C30) for high-sensitivity heterozygote 
detection. For the RTT-like list, average mean read depths of 262×, 99×, 67× and 77× were obtained by HCP, 
TSO, SCv2 and SCv3, respectively. Ninety percent of the targeted bases were covered at C30 by HCP, and for TSO, 
88% of the bases were, while WES was 70% in 2011 and 84% in 2014. These mean coverage results are further 
compared in Fig. 1b, displaying variation among samples with the four methods referring to the mean read depth 
and bases covering C1 and C30. Both the coverage and the uniformity of the capture sequencing were better in 
TSO and WES than HCP. Deepening the coverage data, we analyzed the C1 and C30 of the 16 genes related to 
an RTT-like phenotype included in HCP considering the four approaches. For the C1 and C30 plots (Fig. 2), we 
used the raw CCDS coding exon coordinates as common references to compare as fairly as possible the different 
capture approaches. In this analysis, we discarded the SHANK3 gene since this gene does not have a CCDS ID 
(Fig. 2).
Variant detection. According to diagnostic quality standards, all regions not reaching the required 30× 
must be Sanger sequenced; from HCP samples, 2 regions of the MECP2 gene were sequenced by SS. Non-targets 
were sequenced by SS in TSO and WES. To identify the potential mutations, we checked the variants by match-
ing their affected phenotypes and inheritance patterns of respective genes checked by SS of the index cases and 
their progenitors. Moreover, we considered the pathogenicity predictors (Mutation Tester, Polyphen-2 and Sorts 
Intolerant From Tolerant) and reviewed the literature, the RettBASE: MECP2 Variation Database, the Exome 
Aggregation Consortium (ExAC), HGMD® Professional 2016.4 and The Database of Short Genetic Variation 
(dbSNP). The potentially pathogenic variants detected in the genes that were not MECP2, CDKL5 or FOXG1 are 
shown in Table 1. All results are shown in Supplementary Table S2.
Sanger Sequencing-SS. A total of 1341 patients were studied by SS between 1999 and 2012, and 375 (22 
by MLPA) were genetically diagnosed (28%) with mutations in MECP2, CDKL5 or FOXG1. During this period of 
time, the workflow was to study the four exons of the MECP2 gene to detect SNVs or short indels and MLPA for 
gross rearrangements. Excluding large rearrangements detected by MLPA, a total of 293 patients with RTT classic 
and 36 with atypical phenotypes had mutations in MECP2. Then, the CDKL5 and FOXG1 genes were studied in 
the patients without mutations in MECP2. No patient diagnosed with RTT-classic had mutations in CDKL5 or 
FOXG1, and 15 patients with atypical RTT had mutations in CDKL5 and 9 in the FOXG1 gene.
Haloplex Custom Panel - HCP. A total of 242 patients were studied with HCP between 2012 and 2016, 
and 53 (6 by MLPA) patients were genetically diagnosed (22%). Excluding large rearrangements detected by 
MLPA, 29 patients had mutations in RTT genes and 90% in MECP2. From 18 patients with mutations in RTT-like 
genes, it is remarkable that the majority of these mutations were in the STXBP1 gene, which is associated with 
early infantile epileptic encephalopathy (EIEE4)20, and the TCF4 gene, which is associated with Pitt–Hopkins 
syndrome21.
Figure 2. Comparison of coverage in 17 RTT-like genes. Scatter plots of average of the coverage at C1 and C30 
of all samples analyzed for the four different approaches.
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Num. 
Patients Gene
OMIM 
number Transcript Type of seq. Change cDNAchange Proteinchange dbSNP
Mutation 
taster, SIFT, 
PROVEAN, 
PolyPhen-2 
scores
Potentially pathogenic mutation detected by HCP
2 STXBP1 602926 NM_003165 Missense c.874C>T p.Arg292Cys — Disease causing, 0, 0.996, −7.58
2 STXBP1 602926 NM_003165 Missense c.875G>A p.Arg292His rs796053361 Disease causing, 0, 1, −4.74
1 KCNQ2 602235 NM_172107 Missense c.593G>A p.Arg198Gln rs796052621 Disease causing, 0, 1, −3.58
1 KCNQ2 602235 NM_172107 Missense c.637C>T p.Arg213Trp rs118192203 Disease causing, 0, 1, −7.19
1 SLC2A1 138140 NM_006516 Missense c.805C>T p.Arg269Cys rs200247956 Disease causing, 0, 1, −7.79
1 STXBP1 602926 NM_003165 Missense c.1216C>T p.Arg406Cys rs796053367 Disease causing, 0, 1, −7.86
1 STXBP1 602926 NM_003165 In-frame deletion c.124_126delTCC p.Ser42del — Disease causing, NA, NA, −10.71
1 STXBP1 602926 NM_003165 Splicing variant c.326-3C>G Miss-splicing — NA, NA, NA, NA
1 STXBP1 602926 NM_003165 Missense c.704G>A p.Arg235Gln — Disease causing, 0, 1, −3.79
1 TCF4 602272 NM_001243236 In-frame indel c.1169_1175delTAGAAAGinsAAA p.Leu390Ter — Disease causing, NA, NA, NA
1 TCF4 602272 NM_001243236 Missense c.1733G>A p.Arg578His rs121909123 Disease causing, 0, 1, −4.73
1 TCF4 602272 NM_001243236 Nonsense c.1774C>T p.Gln592Ter — Disease causing, NA, NA, NA
1 TCF4 602272 NM_001243236 Frameshift deletion c.514_517delAAAG p.Lys172PhefsTer61 rs398123561 Disease causing, NA, NA, NA
Potentially pathogenic mutation detected by TSO
1 MEF2C 600662 NM_001193347 Missense c.48C>G p.Asn16Lys —
Disease causing, 
0.013, 0.995, 
−5.35
1 MEF2C 600662 NM_001193347 Frameshift deletion c.989_990delGT p.Gly330AspfsTer7 — Disease causing, NA, NA, NA
1 SCN2A 182390 NM_001040142 Missense c.3631G>A p.Glu1211Lys rs387906684 Disease causing, 0, 0.995, −3.82
1 SCN2A 182390 NM_001040142 Missense c.5317G>A p.Ala1773Thr — Disease causing, 0, 1, −3.68
1 SYNGAP1 603384 NM_006772 Frameshift deletion c.2019delA p.Thr674ProfsTer36 — Disease causing, NA, NA, NA
1 SYNGAP1 603384 NM_006772 Frameshift deletion c.1782delC p.Leu595CysfsTer55 rs587780470 Disease causing, NA, NA, NA
Potentially pathogenic mutation detected by WES
1 CACNA1I 608230 NM_021096 Missense c.4435C>T p.Leu1479Phe —
Disease causing, 
0.397, 0.756, 
−1.53
1 CHRNA5 118505 NM_000745 Missense c.748C>A p.Pro250Thr — Disease causing, 0.301, 1, −6.07
1 GABBR2 607340 NM_005458 Missense c.1699G>A p.Ala567Thr —
Disease causing, 
0.002, 0.999, 
−3.48
1 GRIN2B 138252 NM_000834 Missense c.1657C>A p.Pro553Thr —
Disease causing, 
0.001, 0.975, 
−6.8
1 HCN1 602780 NM_021072 Missense c.1159G>T p.Ala387Ser —
Disease causing, 
0.002, 0.767, 
−2.76
Table 1. Potentially pathogenic and causative SNVs detected, excluding RTT genes. Variant effect predictors 
web tools used: Mutation taster (http://www.mutationtaster.org/); SIFT-PROVEAN, SIFT scores ranged from 
0–1, where 0 is predicted to be most damaging and Protein Variation Effect Analyzer (PROVEAN) score 
≤−2.5, the protein variant is predicted to have a “deleterious” effect, while if the PROVEAN score is >−2.5, the 
variant is predicted to have a “neutral” effect (http://provean.jcvi.org/genome_submit_2.php); and Polyphen-2, 
ranged from 0–1, where 1 is most likely to be damaging (http://genetics.bwh.harvard.edu/pph2/).
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TruSight One panel - TSO. Fifty-one patients were studied by TSO since 2015, and 15 patients were geneti-
cally diagnosed (29%). Three patients had mutations in RTT genes and 12 in RTT-like genes. In these 12 patients, 
we detected 2 SNVs in MEF2C and 2 in SCN2A genes, which are associated with mental retardation, stereotypic 
movements, epilepsy, and/or cerebral malformations22–24; 2 SNVs in the SYNGAP1 gene, which is associated with 
mental retardation24,25; a deletion of IQSEC2 and KDM5C genes, which are associated with mental retardation26; 
a gross deletion in chr15 (chr15:22,833,395-28,567,298), which is associated with Prader-Willi syndrome27; and 
a duplication in chr14 (14q32.11-q32.33(90949120-107287505)), which is associated with mental retardation 
and development delay28. All CNVs detected through the read depth and detected by NGS were confirmed by 
CGHarray.
Whole Exome Sequencing - WES. Twenty-five patients were studied by WES in 2011 (SCv2) and 2014 
(SCv3). Five occurred in genes previously associated with neurodevelopmental disorders with features simi-
lar to those of RTT syndrome. We identified four mutations in genes such as HCN129 and GRIN2B30, which 
are associated with early infantile epileptic encephalopathy; SLC6A1, which is associated with epilepsy and 
myoclonic-atonic seizures31; TCF4, which is associated with Pitt–Hopkins syndrome21; and SCN1A, which is 
associated with Dravet syndrome32. The other potentially pathogenic variants that were identified occurred in 
genes that had not been linked to any genetic disorder33. However, there was an enrichment of genes with a 
potential role in neuronal biology and functionality, such as the gamma-aminobutyric type B receptor subunit 
2 (GABBR2), the neuronal acetylcholine receptor subunit alpha-5 (CHRNA5), and the neuronal voltage-gated 
calcium channel (CACNA1I).
Genetic diagnosis. The total of cases and statistical results of genetic diagnoses of the RTT-like patients are 
listed in Fig. 3a. We identified the genetic cause for 353/1341 patients studied with SS. All characterized patients 
(26.3%) had mutations in RTT genes (MECP2, 24.5%; CDKL5, 1.1%; FOXG1, 0.7%). Forty-seven of 242 patients 
(19.4%) were genetically diagnosed by HCP; for these patients, 7.9% had mutations in the MECP2 gene, 2.9% in 
CDKL5, 1.2% in FOXG1 and 7.4% in other genes related to RTT-like phenotypes. Fifteen of 51 patients (29.4%) 
were genetically diagnosed by TSO; for these patients, 2.0% had mutations in the MECP2 gene, 3.9% in CDKL5 
and 23.5% in other genes related to RTT-like phenotypes. Ten of 25 patients (40.0%) were genetically diagnosed 
by TSO; for these patients, 4.0% had mutations in the MECP2 gene, 4.0% in CDKL5 and 32.0% in other genes 
related to RTT-like phenotypes (Fig. 3b).
In addition of these results, it has been identified by MLPA twenty four patients with gross deletions which 
are not included in the statistical results. Twenty one patients with gross deletions in MECP2, where one have a 
deletion of exon 1 and 2, six patients in exon 3 and fourteen patients in exon 3 and 4. Two patients have a deletion 
in CDKL5, one with a deletion in exon 1 and 2 and other in exon 8. And three patients with a deletion FOXG1.
Discussion
Over the last few years, several genes have been associated with RTT-like phenotypes17,33–37 due to the incorpora-
tion of NGS. Traditional detection methods for individual genes such as SS can only provide a limited mutation 
spectrum of the disease, consuming a great amount of time. NGS, which has revolutionized molecular genetics 
research, is a high-throughput method capable of rapidly sequencing a large number of genes in parallel and pro-
viding large datasets33–38. This study reports a comparison among different sequencing methods used across the 
last decade. We first developed a custom panel for molecular diagnosis of RTT and RTT-like phenotypes covering 
17 genes related to RTT-like disease and then used a commercial panel that includes these genes and others also 
Figure 3. Statistics results for genetic diagnosis. Each columns represents different detection methodology used 
(SS, HCP, TSO and WES) (a) Percentage and total of families characterized and unsolved by the four different 
approaches. (b) Percentage of patients with MECP2, CDKL5, FOXG1, other genes with pathogenic mutations 
and the unsolved cases for the Sanger Sequencing (SS) and the three NGS approaches. Total of mutations found 
are detailed in Table S2.
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associated with the phenotype. Furthermore, we performed WES to identify unsolved families via SS or a custom 
panel.
High performance standards are essential in a clinical diagnostic setting. Even though the mean read depth in 
HCP is ostensibly higher than other methods, with regions covering more than 500×, the uniformity of the cap-
ture is uneven. Figure 1b shows that some samples from different captures are in the border or below the quality 
standards of diagnosis. In spite of the fact that TSO has a slightly lower coverage at C30 than HCP, the homoge-
neity and uniformity of all the samples analyzed is more accurate. Even though the number of target region bases 
not reaching C30 is much higher in WES than in panel sequencing, it should be noted that the quality of the anal-
ysis improved in these few years (2011 to 2014). Moreover, these coverage comparatives could be inequitable, and 
we have to take into account that these WES are not performed with very high coverage and we cannot eliminate 
duplicates of PCR of the HCP. Thus, we not only compared the C30 but also the C1, which is the region that could 
potentially be covered if adequate coverage was made. Comparing the C1, TSO and SCv3 could potentially be 
better coverage than HCP and SCv239.
A large cohort of Spanish patients who exhibited clinical features associated with RTT or RTT-like phenotypes 
was recruited over three decades. Before the implementation of NGS, the cohort of patients was less clinically 
homogenous. Today, the cohort presents an increase in the number of patients who were RTT-like compared to 
classic or atypical RTT. This is likely due to the limitation of the technique because it takes time to analyze the 3 
genes associated with RTT using SS and clinicians only send samples from patients who have fulfilled the clinical 
criteria as RTT.
Regarding additional information of this study, with a more extensive panel, the rate of the families character-
ized was higher. We characterized 40% of the families analyzed by WES and only 26% by SS. It is obviously less 
costly to sequence a panel of patients than an exome per trio (patient and progenitors) due to the much smaller 
capture region. Moreover, the development of panels targeting most clinically relevant genes, such as TSO or 
HCP, would be more cost-effective than standard WES. However, it must be taken into consideration that our 
HCP panel required a cost for development and validation, and TSO and WES are both labelled for research use 
only. For these reasons, proper validation by the laboratory is required before implementation in patient diag-
noses. On the other hand, data obtained in a HCP or TSO are easier to interpret than WES results and also the 
computational requirements for a panel of a few genes is lower than a WES40.
Regarding the NGS results, the MECP2 gene remains the major mutated gene in our cohort (82% of all pos-
itive results), followed by CDKL5 (6%) and FOXG1 (3%) genes. One of the important findings is that two genes 
related to other phenotypes were found to be more frequently mutated than in other RTT-like phenotypes. Eight 
patients had pathogenic mutations in the STXBP1 gene. The clinical features in patients with a mutation in this 
gene, such as developmental regression in the neonatal period or infancy, hypotonia, poor visual pursuit, seizures 
and epileptic encephalopathy, could fit perfectly with the RTT phenotype. Five patients had pathogenic mutations 
in the TCF4 gene and one in the UBE3A gene, which are associated with Pitt-Hopkins syndrome and Angelman 
syndrome, respectively. Mutations in these genes cause severe neurologic features such as poor or absent speech 
development, delayed motor development, seizures, and hypotonia with an onset during the first year of life. 
Moreover, the patients with Pitt-Hopkins have morphologic characteristics, such as deep-set eyes and fleshy 
ears, but in our cohort, we found patients without any of these features. We also found 2 patients with mutations 
in the MEF2C gene (mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations) and 2 
patients with mutations in the SYNGAP1 gene (mental retardation, autosomal dominant 5). The fact that there 
are the same neurologic features commented on previously highlights that SYNGAP1 has behavioral psychiatric 
manifestations identical to RTT, that is, autism features and regression of motor development.
It is also remarkable that, in addition to STXBP1 (EEIE4), we found mutations in genes related to EEIE: 
KCNQ2 (EEIE7), SCN1A (EEIE6), SCN2A (EEIE11), GRIN2B (EEIE27) and HCN1 (EEIE24) genes. Furthermore, 
we also found members of the solute carrier families related to epilepsy: SLC6A1 (myoclonic-atonic epilepsy) and 
SLC2A1 (idiopathic generalized epilepsy) genes33,35.
Finally, mutations in genes without related phenotypes were detected by WES: GABBR2, CHRNA5 and 
CACNA1I. Even though these genes are quite unknown, they have a potential role in neuronal biology and func-
tionality. Further functional studies are required to consider these as the genetic cause of the disease. The clinical 
characteristics and detected variants of these patients are summarized in Lucariello et al.33.
In this study, we focused on the comparison of a single nucleotide variant (SNV) and insertion/deletion 
detection, since these approaches are highly sensitive and specific to detect these types of mutations. Therefore, 
our diagnostics workflow includes MLPA (Multiplex Ligation-dependent Probe Amplification) of the MECP2, 
CDKL5, FOXG1 and TCF4 genes. aCGH (array comparative genomic hybridization) can be used for patients 
who have to be analyzed by WES. Although copy number variations (CNV) are difficult to detect with these NGS 
methods, we performed a preliminary study with TSO read depths of patients without detecting SNVs, trying to 
detect CNVs via bioinformatics methods. We were able to detect 3 de novo pathogenic CNVs corroborated later 
by aCGH: two deletions, one of the IQSEC2 gene and one of the KDM5C gene, and another in chr15:22,833,395-
28,567,298. One gross duplication in the long arm of chr14:90,949,120-107,287,505 was found.
In summary, the genetic study by NGS allows study of a larger number of genes associated with RTT-like 
symptoms simultaneously, allowing genetic study of a wider group of patients10,41. These detected variants iden-
tified by NGS may modify the initial clinical diagnosis to other neurodevelopmental syndromes, or determine 
new candidate genes related to RTT-like symptoms, providing the clinician with more information and clues 
that could help in the prevention of future symptoms or in the pharmacologic therapy. For instance, the use of 
D-serine as a dietary supplement for the enhancement of glutamatergic neurotransmission and/or excitatory/
inhibitory neurotransmitter imbalance affected in patients with mutations in N-Methyl-D-aspartate receptors 
such as GRIN2B gene42.We could conclude that TSO has the best cost-efficiency of all technologies used and 
could offer timely responses for clinical diagnosis. However, performing a WES in families to characterize the 
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family and identify new candidate genes should be included in the target panels. In addition, study of the pro-
genitors remains essential for their characterization as well as the need for functional studies in newly discovered 
genetic variants.
Material and Methods
Patients and DNA extraction. A cohort of 1577 Spanish patients who exhibited clinical features asso-
ciated with RTT or RTT-like phenotypes was recruited at Sant Joan de Déu Hospital in Barcelona, Spain, from 
different Spanish Hospitals. Genomic DNA samples were extracted from peripheral blood leukocytes using the 
Puregene DNA Isolation kit (Gentra System, Minneapolis, USA) following the manufacturer’s instructions. All 
DNA samples were quantified using a Qubit 2.0 Fluorometer (Invitrogen), and the DNA purity was quantified by 
calculating the absorbance ratio (A260/280) with a NanoDrop 1000 (Thermo Fisher).
Ethical issues. The study was approved by the ethical committees of Hospital Sant Joan de Déu, CEIC: 
Comité d’Ètica d’Investigación Clinica- Fundació Sant Joan de Déu (internal code: PIC-101-15). Patients or their 
parents signed informed consent for genetic studies, and tissue samples from patients and controls were obtained 
according to the Helsinki Declaration of 1964, as revised in 2001.
Molecular analysis. A total of 1341 patients were sequenced by SS for the 3 RTT genes (MECP2, CDKL5 and 
FOXG1); 242 patients by HCP; 51 patients by TSO; and 24 patients with their healthy progenitors by WES. All 
patients analyzed by WES had an aCGH performed first with a normal or inconclusive profile.
Copy Number Variations - CNVs. Multiplex Ligation-dependent Probe Amplif ication 
(MLPA). MECP2-MLPA was performed using a SALSA kit P015, CDKL5-MLPA with a SALSA kit P189 and 
FOXG1-TCF4-MLPA with a SALSA kit P075 (MRC-Holland, Amsterdam, The Netherlands) according to the 
manufacturer’s instructions.
Array Comparative Genomic Hybridization (aCGH). The aCGH analysis was performed at Bioarray (Genetic 
diagnosis, Alicante, Spain) using two different platforms: human genome Cytoarray Plus 180K and 400K (Agilent 
Technologies, Santa Clara, CA, USA). All genomic coordinates are in build GRCh37/hg19.
NGS: Library Preparation. Library preparation was conducted according to the manufacturers’ instruc-
tions. HCP and TSO panels were created at Sant Joan de Déu Hospital and WES at the National Center for 
Genomic Analysis (CNAG).
Haloplex Custom Panel (HCP). We designed a custom-made panel with 17 genes associated with a RTT-like 
phenotype based on the evidence curated in the Online Mendelian Inheritance in Man (OMIM). The genes are 
shown in Supplementary Table S3. Amplicon libraries were prepared using the Agilent HaloPlex Target enrich-
ment system, for Illumina paired-end multiplexed sequencing platforms (Agilent Technologies), according to 
the manufacturer’s sample preparation protocol. Briefly, 225 ng of genomic DNA was digested with restriction 
enzymes. The hybridization was performed for 3 hours at 54 °C, and the circularized target DNA-HaloPlex 
probe hybrids, containing biotin, were captured on streptavidin beads (HaloPlex Magnetics Beads, Agilent 
Technologies). The DNA with adaptor-modified ends was PCR amplified (number of cycles depended on the 
lot, Herculase II fusion DNA polymerase, Agilent). The amplified target DNA was purified using AMPure XP 
beads (Beckman Coulter Genomics, GENEWIZ, New Jersey, USA). All of the DNA samples were individually 
indexed. Amplification of the libraries was performed on a GeneAmp®PCR System 9700 thermocycler (Applied 
Biosystems). The restriction digestion and amplicon library quantities were quality evaluated using a Bioanalyzer 
High Sensitivity DNA Assay kit in an Agilent 2100 Bioanalyzer (Agilent Technologies) and quantified using a 
Qubit 2.0 Fluorometer (Invitrogen).
TruSight One Panel (TSO). TruSight One Sequencing Panel (Illumina, San Diego, CA) targeted 4,813 genes 
associated with a clinical phenotype. Libraries were generated using the TruSight OneTM Sequencing Panel kit 
with the TruSight OneTM Sequencing Panel (Illumina), according to the manufacturer’s sample preparation pro-
tocol. Briefly, 50 ng of each DNA sample was enzymatically fragmented and adapter sequences were added to the 
ends. The fragmented DNA was purified, and barcodes and common adapters required for cluster generation and 
sequencing were PCR-added. After cleanup, 500 ng of each of the 12 DNA libraries was pooled. Then the libraries 
were hybridized twice to specific capture probes; the unhybridized material was washed away, and the captured 
fragments were amplified using PCR followed by purification. The enriched libraries were quantified using a 
Qubit 2.0 Fluorometer, and their quality was evaluated using a Bioanalyzer 2100 and the High Sensitivity DNA 
Kit (Agilent Technologies). Libraries were diluted and pooled to obtain the final sequencing equimolar pool.
Whole Exome Sequencing (WES). For whole exomes from 2011, the sample preparation for capturing approx-
imately 44 Mb of selected human genome regions was performed according to the NimbleGen SeqCap EZ 
Exome Libray SR protocol, v2.2, for Illumina paired-end sample libraries with modifications included in draft 
v1.4 (February 2011). In brief, 1.0 μg of genomic DNA was sheared on a Covaris™ E210 instrument (Covaris). 
The fragment size (150–400 bp) and the quantity were confirmed with the Agilent 2100 Bioanalyzer 1000 chip 
(Agilent). Fragmented DNA was prepared using an Illumina TruSeq DNA Sample Preparation Kit (Illumina) 
following the protocol described in the Illumina TruSeq DNA Sample Preparation Guide (revision A, November 
2010) with the exception of the fragment size selection using an Agencourt SPRI XP Kit (Beckman Coulter). 
Instead of the standard Illumina PCR enrichment step, amplification via pre-capture LM-PCR (8 cycles) was 
performed with a SeqCap EZ Human Exome Kit v2.0 (Roche NimbleGen). One microgram of the amplified 
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library was hybridized to EZ probes at 47 °C for 72 hrs. After washing and recovery of the captured DNA, the 
library was amplified through post-capture LM-PCR (18 cycles). The final product was quality controlled on a 
Bioanalyzer DNA 1000 chip, and the success of the enrichment was measured with a qPCR SYBR Green assay 
on a LightCycler® 480 Instrument (Roche), evaluating one genomic locus with pre- and post-captured material.
For whole exomes from 2014, the NimbleGen SeqCap EZ v3.0 system for exome enrichment was used and 
pre-capture multiplexing was applied following the manufacturer's protocol version 4.2. Briefly, 1 μg of genomic 
DNA was fragmented with Covaris ™E210 and used for ligation of the adapters containing Illumina specific 
indexes with a KAPA Library Preparation kit (Kapa Biosystems). Adapter ligation DNA fragments were enriched 
by 7 cycles of pre-capture PCR using KAPA HiFi HotStart ReadyMix (2×) (Kapa Biosystems) and analyzed on an 
Agilent 2100 Bioanalyzer with the DNA 1000 assay. Five libraries were pooled with a combined mass of 1250 ng 
for the baits hybridization step (47 °C; 68 hrs). After washing (47 °C), the multiplexed captured library was recov-
ered with capture beads and amplified with 14 cycles of post-capture PCR using KAPA HiFi HotStart ReadyMix 
(2×). The size, concentration and quality of the captured library were determined using an Agilent DNA 1000 
chip. The success of the enrichment was measured using a qPCR SYBR Green assay on a Roche LightCycler® 480 
Instrument evaluating one genomic locus with pre- and post-captured material.
NGS: Run. HPC and TSO libraries were sequenced on an Illumina Miseq instrument and NextSeq 500, 
respectively, following the manufacturer’s protocol, with a paired end run. Each WES (2011 and 2014) library was 
sequenced on an Illumina HiSeq 2000 instrument in a fraction of a sequencing lane following the manufacturer’s 
protocol, with a paired end run of 2×101 bp. Image analysis, base calling and quality scoring of the run were 
processed using the manufacturer’s software Real Time Analysis (RTA 1.10.36 and RTA 1.13.48) and followed by 
generation of FASTQ sequence files by CASAVA.
NGS: Data Analysis. HPC and TSO data analyses were performed at Genycell Biotech S.L. (Madrid, Spain). 
Briefly, both panel sequencing reads were trimmed from the 3′ end up to the first base with a Phred quality >9 
and were mapped to the Human genome reference v37 with decoy sequences [hs37d5] (Broad, ftp://ftp.1000ge-
nomes.ebi.ac.uk/vol1/ftp/technical/reference/phase2_reference_assembly_sequence/hs37d5.fa.gz) using the 
BWA-MEM version 0.7.5a. (bio-bwa.sourceforge.net/). To calculate read statistics, we used Prinseq-lite version 
0.20.3 lite (prinseq.sourceforge.net/) and Picard Calculate HS Metrics version 1.119 (http://picard.sourceforge.
net) to calculate metrics. Alignment (.bam) files containing only properly paired and uniquely mapped reads were 
processed with Picard Mark Duplicates version 1.119 to remove duplicates, and local realignment was performed 
with Freebayes version 9.9.13 (https://github.com/ekg/freebayes)43. SAMtools version 0.1.19 (http://samtools.
sourceforge.net/)44 was used on the processed BAM files to call single nucleotide variants (SNVs) and small inser-
tion deletions (INDELs). Functional annotations from Ensembl release 75 (GRCh37.75 database)45 were added 
to the resulting.vcf files using the Genome Analysis Tool Kit (GATK) version 2.4 (https://www.broadinstitute.
org/gatk/)46 to annotate variants with dbSNP version 137 and Ensembl Variant Effect Predictor version 72 (http://
www.ensembl.org/info/docs/tools/vep/index.html) to annotate the variants.
For each WES (2011 and 2014), sequencing reads were trimmed from the 3′ end up to the first base with a 
Phred quality >9 and were mapped to the Human genome reference v37 with decoy sequences [hs37d5] using 
the GEM toolkit47. Alignment (.bam) files containing only properly paired and uniquely mapped reads were 
processed with Picard tools version 1.110 (http://picard.sourceforge.net) to remove duplicates, and local realign-
ment was performed with the Genome Analysis Tool Kit (GATK) version 3.1 (https://www.broadinstitute.org/
gatk/)46. For alignments and coverage metrics, it has been remapped with BWA-MEM version 0.7.5a48. To call 
single nucleotide variants (SNVs) and small insertion deletions (INDELs) on the processed alignment (.bam) 
file, we used SAMtools version 0.1.19 (http://samtools.sourceforge.net/)44. Functional annotations from Ensembl 
release 75 were added to the resulting VCF using snpEff (http://snpeff.sourceforge.net/)49. SNPSift (http://snpeff.
sourceforge.net/ SnpSift.html)50 was used to add information from dbSNP version 137, population frequencies 
from 1000 Genomes and the Exome Variant Server51, the NHLBI Exome Sequencing Project (http://evs.gs.wash-
ington.edu/EVS/) and a variety of conservation and deleteriousness predictions included in dbNSFP version 2.5 
(http://sites.google.com/site/jpopgen/dbNSFP)52.
Sanger validation. The identified variants and familial segregation studies were validated by SS. The spe-
cific primers were designed online by Primer3 version 0.4.0 (http://bioinfo.ut.ee/primer3-0.4.0/primer3/). The 
PCR products were sequenced using a Big-Dye® Terminator version 3.1 Cycle Sequencing Kit in an Applied 
Biosystems 3730/DNA Analyzer (Applied BioSystems, Waltham, Massachusetts, USA). The raw data were ana-
lyzed with Chromas trace viewer (http://technelysium.com.au/wp/chromas/). The primers used for SS are shown 
in Supplementary Table S4.
References
 1. Rett, A. On a unusual brain atrophy syndrome in hyperammonemia in childhood. Wien. Med. Wochenschr. 116, 723–726 (in 
German) (1966).
 2. Hagberg, B., Aicardi, J., Dias, K. & Ramos, O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use 
in girls: Rett’s syndrome: report of 35 cases. Ann Neurol 14, 471–479 (1983).
 3. Laurvick, C. L. et al. Rett syndrome in Australia: a review of the epidemiology. J Pediatr 148, 347–352 (2006).
 4. Diagnostic criteria for Rett syndrome. The Rett Syndrome Diagnostic Criteria Work Group. Ann Neurol 23, 425–428 (1988).
 5. Hagberg, B., Hanefeld, F., Percy, A. & Skjeldal, O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments 
to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, 
Germany, 11 September 2001. Eur J Paediatr Neurol 6, 293–297 (2002).
 6. Neul, J. L. et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 68, 944–950 (2010).
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 12288  | DOI:10.1038/s41598-017-11620-3
 7. Amir, R. E. et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23, 
185–188 (1999).
 8. Miltenberger-Miltenyi, G. & Laccone, L. Mutations and Polymorphisms in the Human Methyl CpG-Binding Protein MECP2. Mut 
Genet 135, 1343–1354 (2003).
 9. Christodoulou, J., Grimm, A., Maher, T. & Bennetts, B. RettBASE: the IRSA MECP2 variation database — a new mutation database 
in evolution. Hum Mutat 21, 466–472 (2003).
 10. Neul, J. L. et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 70, 
1313–1321 (2008).
 11. Chao, H. T. et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468, 
263–269 (2010).
 12. Neul, J. L. et al. Developmental delay in Rett syndrome: data from the natural history study. J Neurodev Disord 6, 20 (2014).
 13. Kalscheuer, V. M. et al. Mutations in the polyglutamine binding protein 1 gene cause X-linked mental retardation. Nat Genet 35, 
313–315 (2003).
 14. Ariani, F. et al. FOXG1 is responsible for the congenital variant of Rett syndrome. Am J Hum Genet 83, 89–93 (2008).
 15. Armani, R. et al. Transcription factor 4 and myocyte enhancer factor 2C mutations are not common causes of Rett syndrome. Am J 
Med Genet A 158A, 713–719 (2012).
 16. Zhu, X. et al. Whole-exome sequencing in undiagnosed genetic disorders: interpreting 119 trios. Genet Med 17, 774–781 (2015).
 17. Sajan, S. A. et al. Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2. 
Genet Med 19, 13–19 (2017).
 18. Sikkema-Raddatz, B. et al. Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat 
34, 1035–1042 (2013).
 19. Kurian, A. W. et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32, 
2001–2009 (2009).
 20. Carvill, G. L. et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology 14, 1245–1253 (2014).
 21. Sweatt, J. D. Pitt-Hopkins Syndrome: intellectual disability due to loss of TCF4-regulated gene transcription. Exp Mol Med 45, e21 
(2013).
 22. Zweier, M. et al. Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental 
retardation and diminish MECP2 and CDKL5 expression. Hum Mutat 6, 722–733 (2010).
 23. Bienvenu, T., Diebold, B., Chelly, J. & Isidor, B. Refining the phenotype associated with MEF2C point mutations. Neurogenetics 14, 
71–75 (2013).
 24. Carvill, G. L. et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat 
Genet 45, 825–830 (2013).
 25. Mignot, C. et al. Genetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy. J Med 
Genet 53, 511–522 (2016).
 26. Fieremans, N. et al. Microdeletion of the escape genes KDM5C and IQSEC2 in a girl with severe intellectual disability and autistic 
features. Eur J Med Genet 58, 324–327 (2015).
 27. Buiting, K. Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C Semin Med Genet 154C, 365–376 (2010).
 28. Thiel, C. T. et al. A de novo 7.6 Mb tandem duplication of 14q32.2-qter associated with primordial short stature with neurosecretory 
growth hormone dysfunction, distinct facial anomalies and mild developmental delay. Eur J Med Genet 51, 362–367 (2008).
 29. Nava, C. et al. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. Nat Genet 46, 640–645 (2014).
 30. Lemke, J. R. et al. GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy. Ann Neurol 75, 147–154 
(2014).
 31. Carvill, G. L. et al. Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic Seizures. Am J Hum Genet 
96, 808–815 (2015).
 32. Brunklaus, A. & Zuberi, S. M. Dravet syndrome–from epileptic encephalopathy to channelopathy. Epilepsia 55, 979–984 (2014).
 33. Lucariello, M. et al. Whole exome sequencing of Rett syndrome-like patients reveals the mutational diversity of the clinical 
phenotype. Hum Genet 135, 1343–1354 (2016).
 34. Olson, H. E. Mutations in Epilepsy and Intellectual Disability Genes in Patients with Features of Rett Syndrome. Am J Med Genet 
167A, 2017–2025 (2015).
 35. Gold, W. A. & Christodoulou, J. The utility of next-generation sequencing in gene discovery for mutation-negative patients with Rett 
syndrome. Front Cell Neurosci 9, 266 (2015).
 36. Lopes, F. et al. Identification of novel genetic causes of Rett syndrome-like phenotypes. J Med Genet 2016. 53, 190–199 (2016).
 37. Marx, V. Next-generation sequencing: The genome jigsaw. Nature 501, 263–268 (2013).
 38. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 
43, 491–498 (2011).
 39. Samorodnitsky, E. et al. Comparison of Custom Capture for Targeted Next-Generation DNA Sequencing. J Mol Diagn 17, 64–75 
(2015).
 40. Sun, Y. et al. Next-Generation Diagnostics: Gene Panel, Exome, or Whole Genome? Hum Mutat 36, 648–655 (2015).
 41. Bebbington, A. et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology 70, 
868–875 (2008).
 42. Soto, D. et al. Rett-like severe encephalopathy caused by a de novo GRIN2Bmutation is attenuated by D-serine dietary supplement. 
Biol Psychiatry S0006-3223, 31671–2, doi:https://doi.org/10.1016/j.biopsych.2017.05.028 (2017).
 43. Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:1207.3907 [q-bio.GN] 
(2012).
 44. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics (Oxford, England) 25, 2078–2079 (2009).
 45. Cunningham, F. et al. Ensembl 2015. Nucleic Acids Res 43, D662–669 (2015).
 46. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. 
Genome Res 20, 1297–1303 (2010).
 47. Marco-Sola, S., Sammeth, M., Guigó, R. & Ribeca, P. The GEM mapper: fast, accurate and versatile alignment by filtration. Nat 
Methods 9, 1185–1188 (2012).
 48. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv preprint arXiv:1303.3997 [q-bio.GN] 
(2013).
 49. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the 
genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6, 80–92 (2012).
 50. Cingolani, P. et al. Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, 
SnpSift. Front genet 3, 35 (2012).
 51. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29, 308–311 (2001).
 52. Liu, X., Jian, X. & Boerwinkle, E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and 
annotations. Hum mutat 34, E2393–2402 (2013).
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7: 12288  | DOI:10.1038/s41598-017-11620-3
Acknowledgements
We thank all patients and their families who contribute to this study. The work was supported by grants from 
the Spanish Ministry of Health (Instituto de Salud Carlos III/FEDER, PI15/01013); Crowdfunding program 
PRECIPITA, from the Spanish Ministry of Health (Fundación Española para la Ciencia y la Tecnología); Catalan 
Association for Rett Syndrome; Fondobiorett and Mi Princesa Rett. The molecular analyses of eleven WES in 
2014 were funded by the CNAG’s 2013 call "300 exomes to elucidate rare diseases”. AGC is supported by the ISCIII 
grant: FIS PI15/01082. 
Author Contributions
J.A. and M.P. conceived and supervised the study. S.V., P.P., N.B., E.G. and L.B., performed the experiments and 
collected the data. J.A., S.V., N.B., P.P., E.G., S.D., J.T. analyzed the results. J.A., M.’O.C., A.G.C., M.P. provided 
samples and patients’ clinical and genetic information. S.V., J.A., J.T., S.D. wrote the manuscript. All the authors 
reviewed the article critically for intellectual content.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-11620-3
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 12288  | DOI:10.1038/s41598-017-11620-3
Consortia
Rett Working Group
Francisco Javier Aguirre7, Montserrat Aleu8, Xènia Alonso4, Mercè Alsius9, Maria Inmaculada 
Amorós10, Guillermo Antiñolo11, Lourdes Aquino12, Carmen Arellano13, Gema Arriola14, Rosa 
Arteaga15, Neus Baena16, Montserrat Barcos17, Nuria Belzunces18, Susana Boronat19, Tomás 
Camacho20, Jaume Campistol4, Miguel del Campo19, Andrea Campo11, Ramon Cancho21, Ramon 
Candau11, Ignacio Canós22, María del Carmen Carrascosa23, Francisco Carratalá-Marco24, Jovaní 
Casano25, Pedro Castro26, Ana Cobo27, Jaime Colomer4, David Conejo28, Maria José Corrales29, 
Rocío Cortés30, Gabriel Cruz31, Gábor Csányi32, María Teresa de Santos33, María de Toledo34, 
Mireia Del Toro19, Rosario Domingo35, Anna Duat36, Rosario Duque37, Ana María Esparza25, Rosa 
Fernández38, Maria Carme Fons4, Ana Fontalba15, Enrique Galán39, Pia Gallano32, María José 
Gamundi13, Pedro Luis García40, María del Mar García41, María García-Barcina42, María Jesús 
Garcia-Catalan4, Sixto García-Miñaur43, Juan Jose Garcia-Peñas36, María Teresa García-Silva44, 
Rosa Gassio4, Esther Geán4, Belén Gil38, Sarenur Gökben45, Luis Gonzalez36, Veronica Gonzalez4, 
Julieta Gonzalez4, Gloria González18, Encarna Guillén35, Miriam Guitart16, Montserrat Guitet46, 
Juan Manuel Gutierrez47, Eva Gutiérrez33, Jose Luís Herranz15, Gemma Iglesias48, Iva Karacic49, 
Carlos H. Lahoz50, José Ignacio Lao51, Pablo Lapunzina43, María Jesús Lautre-Ecenarro52, María 
Dolores Lluch53, Laura López36, Asunción López-Ariztegui54, Alfons Macaya19, Rosario Marín55, 
Charles M. Lourenço Marquez56, Elena Martín44, Beatriz Martínez38, Eduardo Martínez-Salcedo57, 
María José Mas58, Gonzalo Mateo14, Pilar Mendez39, Amparo Morant Jimenez59, Sira Moreno60, 
Fernando Mulas61, Juan Narbona62, Andrés Nascimento4, Manuel Nieto11, Tania Fabiola Nunes4, 
Núria Núñez19, María Obón9, Ignacio Onsurbe23, Carlos Ignacio Ortez4, Emilio Orts29, Francisco 
Martinez22, Rafael Parrilla63, Samuel Ignacio Pascual43, Ana Patiño64, Maria Pérez-Poyato4, Belén 
Pérez-Dueñas4, Pilar Póo4, Eliodoro Puche35, Feliciano Ramos65, Miquel Raspall19, Ana Roche4, 
Susana Roldan66, Jordi Rosell67, Cesar Ruiz68, María Luz Ruiz-Falcó36, Maria Eugenia Russi4, 
Jordi Samarra69, Victoria San Antonio52, Ivan Sanchez4, Xavier Sanmartin4, Ana Sans4, Alfredo 
Santacana70, Sabine Scholl-Bürgi71, Nuria Serrano72, Mercedes Serrano4, Pilar Martin-Tamayo23, 
Adrián Tendero43, Jaime Torrents73, Diego Tortosa35, Emma Triviño74, Ledia Troncoso30, Eulalia 
Turrón32, Pilar Vázquez26, Carlos Vázquez70, Ramón Velázquez43, Clara Ventura19, Alfonso 
Verdú40, Anna Vernet4, M. Tomás Vila75 & Cristina Villar4
7Hospital Torrecardenas, Almeria, Spain. 8Consorcio Hospital General Universitario de Valencia, Valencia, Spain. 
9Hospital Universitari Dr. Josep Trueta, Girona, Spain. 10Hospital Punta Europa, Cadiz, Spain. 11Hospital Universitario 
Virgen del Rocio, Sevilla, Spain. 12Hospital de Mataró, Mataro, Spain. 13Consorci Sanitari, Terrassa, Spain. 14Hospital 
universitario de Guadalajara, Guadalajara, Spain. 15Hospital Universitario Marqués de Valdecilla, Santander, Spain. 
16Hospital de Sabadell, Barcelona, Spain. 17Hospital Universitario Reina Sofía, Cordoba, Spain. 18Balagué Center, 
Barcelona, Spain. 19Hospital de la Vall d’Hebrón, Barcelona, Spain. 20Lema & Bandin Laboratorios, Vigo, Spain. 
21Hospital Universitario Río Hortega, Valladolid, Spain. 22Hospital Universitario Doctor Peset, Valencia, Spain. 23Hospital 
General Universitario de Albacete, Albacete, Spain. 24Hospital Universitari San Juan, Alicante, Spain. 25Hospital 
Universitario General de Castellón, Castellon de la Plana, Spain. 26Hospital Gregorio Marañón, Madrid, Spain. 27Hospital 
de Donostia, San Sebastian, Spain. 28Complejo asistencial, Burgos, Spain. 29Hospital General Mancha Centro, Ciudad 
Real, Spain. 30Hospital San Borja Arriaran, Santiago, Chile. 31Hospital Universitario de Valme, Sevilla, Spain. 32Hospital 
de la Santa Creu i Sant Pau, Barcelona, Spain. 33Hospital de Fuenlabrada, Madrid, Spain. 34Hospital Universitario Severo 
Ochoa, Madrid, Spain. 35Hospital Infantil de La Arrixaca, Murcia, Spain. 36Hospital Infantil Universitario Niño Jesús, 
Madrid, Spain. 37Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain. 38Hospital 
Universitario de Getafe, Madrid, Spain. 39Hospital Materno-Infantil de Badajoz, Badajoz, Spain. 40Hospital Virgen de la 
Salud, Toledo, Spain. 41Hospital Cormarcal de Figueres, Girona, Spain. 42Hospital de Basurto, Bilbao, Spain. 43Hospital 
La Paz, Madrid, Spain. 44Hospital Universitario 12 de Octubre, Madrid, Spain. 45Ege Ünŭversŭtesŭ Tip Fakültesŭ 
Pedŭatrŭ AD, Uzmur, Turkey. 46Hospital General de Granollers, Barcelona, Spain. 47Hospital Clínico Universitario de 
Valladolid, Valladolid, Spain. 48Hospital Virgen de la Luz, Cuenca, Spain. 49Clinical Hospital Center Zagreb, Zagreb, 
Croatia. 50Hospital Central Asturias, Asturias, Spain. 51Laboratorio Echevarne, Barcelona, Spain. 52Hospital Clínico San 
Carlos, Madrid, Spain. 53Hospital Universitario Virgen Macarena, Sevilla, Spain. 54Hospital de Cruces, Bilbao, Spain. 
55Hospital Universitario Puerta del Mar, Cadiz, Spain. 56Medical Genetics Service, Clinics Hospital of Ribeirão Preto, 
University of São Paulo, Sao Paulo, Brazil. 57Hospital General Universitario de Alicante, Alicante, Spain. 58Hospital Joan 
XXIII, Tarragona, Spain. 59Centro privado, Valencia, Spain. 60Hospital Virgen del Camino, Pamplona, Spain. 61Instituto 
Valenciano de Neurociencias, Valencia, Spain. 62Clínica Universitaria de Pamplona, Pamplona, Spain. 63Complejo 
Hospitalario de Jaén, Jaen, Spain. 64Hospital de Navarra, Navarra, Spain. 65Hospital Clínico Universitario Lozano 
Blesa, Zaragoza, Spain. 66Hospital Universitario Virgen de las Nieves, Granada, Spain. 67Hospital Son Dureta, Palma 
de Mallorca, Spain. 68Hospital Costa del Sol, Malaga, Spain. 69Hospital General de Vic, Barcelona, Spain. 70Complejo 
Hospitalario Universitario Insular, Las Palmas de Gran Canaria, Spain. 71Medizinische Universität Innsbruck, Innsbruck, 
Austria. 72Althaia, Manresa, Spain. 73Reference Laboratory, Barcelona, Spain. 74Catlab, Barcelona, Spain. 75Hospital 
Francesc De Borja, Valencia, Spain. 
